SynthesisFrontiers in nutrition2026
Associations of sarcopenia and sarcopenic obesity with hypertension: a systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia and sarcopenic obesity have been increasingly investigated in relation to hypertension, but observational findings remain inconsistent. This systematic review and meta-analysis aimed to quantitatively synthesize the associations of sarcopenia and sarcopenic obesity with hypertension in adults. Methods: PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to July 20, 2026. Observational studies reporting associations of sarcopenia or sarcopenic obesity with hypertension were included. Effect estimates were pooled using random-effects restricted maximum likelihood models. Subgroup analyses were conducted according to study design, age, sarcopenia diagnostic criteria, and hypertension definition. Exploratory stratified analyses were additionally performed according to effect measure type [odds ratio (OR) versus hazard ratio (HR)]. The protocol was registered in PROSPERO (CRD420261393787). Results: Nine studies involving 346,748 participants were included. Sarcopenia was significantly associated with hypertension (pooled relative effect estimate: 1.45, 95% CI: 1.08-1.94; Conclusion: Sarcopenia and sarcopenic obesity were both significantly associated with hypertension. However, substantial heterogeneity and the observational nature of the evidence warrant cautious interpretation and preclude causal inference. Further prospective studies using harmonized definitions and diverse populations are needed to clarify temporality, sources of heterogeneity, and potential clinical implications. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261393787, identifier CRD420261393787.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.